company background image
BXRX.Q logo

Baudax Bio OTCPK:BXRX.Q Stock Report

Last Price

US$0.016

Market Cap

US$839.4k

7D

0%

1Y

-99.1%

Updated

27 Mar, 2024

Data

Company Financials

BXRX.Q Stock Overview

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings.

BXRX.Q fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Baudax Bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Baudax Bio
Historical stock prices
Current Share PriceUS$0.016
52 Week HighUS$3.47
52 Week LowUS$0.012
Beta1.58
1 Month Change-30.43%
3 Month Change-41.39%
1 Year Change-99.06%
3 Year Change-100.00%
5 Year Changen/a
Change since IPO-100.00%

Recent News & Updates

Recent updates

Baudax Bio stock down after pricing $6.2M equity offering

Aug 30

Baudax Bio to get US patent linked to pain drug Anjeso

Aug 22

Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M

Aug 11

Cosette Pharmaceuticals appoints Rick Casten as CFO

Jul 06

Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds

Sep 09

A First Look At Baudax Bio

May 30

Baudax Bio EPS misses by $0.08, misses on revenue

May 05

Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty

Apr 26

Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Feb 17
Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Baudax Bio EPS of $0.62

Nov 09

Baudax Bio: Why I'm Catching This Falling Knife

Nov 03

Shareholder Returns

BXRX.QUS PharmaceuticalsUS Market
7D0%-0.2%0.6%
1Y-99.1%23.9%29.5%

Return vs Industry: BXRX.Q underperformed the US Pharmaceuticals industry which returned 23.9% over the past year.

Return vs Market: BXRX.Q underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is BXRX.Q's price volatile compared to industry and market?
BXRX.Q volatility
BXRX.Q Average Weekly Movement21.8%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: BXRX.Q's share price has been volatile over the past 3 months.

Volatility Over Time: BXRX.Q's weekly volatility has decreased from 37% to 22% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20199Gerri Henwoodhttps://www.baudaxbio.com

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies.

Baudax Bio, Inc. Fundamentals Summary

How do Baudax Bio's earnings and revenue compare to its market cap?
BXRX.Q fundamental statistics
Market capUS$839.36k
Earnings (TTM)-US$59.20m
Revenue (TTM)US$1.27m

0.7x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BXRX.Q income statement (TTM)
RevenueUS$1.27m
Cost of RevenueUS$7.01m
Gross Profit-US$5.74m
Other ExpensesUS$53.46m
Earnings-US$59.20m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.13
Gross Margin-452.32%
Net Profit Margin-4,665.25%
Debt/Equity Ratio-436.4%

How did BXRX.Q perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.